These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35472491)

  • 1. Clinical and genetic characterization and long-term evaluation of individuals with maturity-onset diabetes of the young (MODY): The journey towards appropriate treatment.
    Campos Franco P; Santos de Santana L; Dantas Costa-Riquetto A; Santomauro Junior AC; Jorge AAL; Gurgel Teles M
    Diabetes Res Clin Pract; 2022 May; 187():109875. PubMed ID: 35472491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights from basic adjunctive examinations of GCK-MODY, HNF1A-MODY, and type 2 diabetes: A systemic review and meta-analysis.
    Liu J; Xiao X; Zhang Q; Yu M
    J Diabetes; 2023 Jun; 15(6):519-531. PubMed ID: 37226652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
    Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
    Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MODY in Ukraine: genes, clinical phenotypes and treatment.
    Globa E; Zelinska N; Elblova L; Dusatkova P; Cinek O; Lebl J; Colclough K; Ellard S; Pruhova S
    J Pediatr Endocrinol Metab; 2017 Oct; 30(10):1095-1103. PubMed ID: 28862987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maturity-onset diabetes of the young (MODY) in Brazil: Establishment of a national registry and appraisal of available genetic and clinical data.
    Giuffrida FMA; Moises RS; Weinert LS; Calliari LE; Manna TD; Dotto RP; Franco LF; Caetano LA; Teles MG; Lima RA; Alves C; Dib SA; Silveiro SP; Dias-da-Silva MR; Reis AF;
    Diabetes Res Clin Pract; 2017 Jan; 123():134-142. PubMed ID: 28012402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing.
    López-Garrido MP; Herranz-Antolín S; Alija-Merillas MJ; Giralt P; Escribano J
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):342-7. PubMed ID: 23009393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
    Nowak N; Hohendorff J; Solecka I; Szopa M; Skupien J; Kiec-Wilk B; Mlynarski W; Malecki MT
    Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
    Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
    Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maturity onset diabetes of the young (MODY) in Chinese children: genes and clinical phenotypes.
    Ming-Qiang Z; Yang-Li D; Ke H; Wei W; Jun-Fen F; Chao-Chun Z; Guan-Ping D
    J Pediatr Endocrinol Metab; 2019 Jul; 32(7):759-765. PubMed ID: 31216263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients.
    Szopa M; Osmenda G; Wilk G; Matejko B; Skupien J; Zapala B; Młynarski W; Guzik T; Malecki MT
    Eur J Endocrinol; 2015 Mar; 172(3):277-83. PubMed ID: 25501962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Italian MODY family with proband and son carrying variants in GCK and HFN1A: is it a true case of digenic MODY?
    Lucchesi D; Randazzo E; Del Prato S; Bianchi C
    Acta Diabetol; 2024 Jan; 61(1):131-134. PubMed ID: 37730861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
    Fendler W; Borowiec M; Antosik K; Szadkowska A; Deja G; Jarosz-Chobot P; Mysliwiec M; Wyka K; Pietrzak I; Skupien J; Malecki MT; Mlynarski W
    Clin Endocrinol (Oxf); 2011 Sep; 75(3):321-7. PubMed ID: 21521320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
    Pal A; Farmer AJ; Dudley C; Selwood MP; Barrow BA; Klyne R; Grew JP; McCarthy MI; Gloyn AL; Owen KR
    Diabetes Care; 2010 Feb; 33(2):252-7. PubMed ID: 19933992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maturity-onset diabetes of the young (MODY): an update.
    Anık A; Çatlı G; Abacı A; Böber E
    J Pediatr Endocrinol Metab; 2015 Mar; 28(3-4):251-63. PubMed ID: 25581748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
    Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
    Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
    Owen KR; Thanabalasingham G; James TJ; Karpe F; Farmer AJ; McCarthy MI; Gloyn AL
    Diabetes Care; 2010 Sep; 33(9):1919-24. PubMed ID: 20724646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young.
    Ellard S; Colclough K
    Hum Mutat; 2006 Sep; 27(9):854-69. PubMed ID: 16917892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment.
    Schnedl WJ; Holasek SJ; Schenk M; Enko D; Mangge H
    Wien Klin Wochenschr; 2021 Mar; 133(5-6):241-244. PubMed ID: 33245425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.